Key Highlights

  • The June quarter beat on both Revenue and adjusted EPS, but full-year 2026 guidance was reduced for the second straight quarter, organic growth to 5–6%, adjusted EPS to $3.28–$3.32, and the shares still closed flat on the day, on roughly double normal Volume .
  • The damage is concentrated: Watchman grew about 4% organically after almost 30% in 2025, and US electrophysiology is losing pulsed field ablation share now that PFA is 80–85% of the US ablation market. Interventional cardiology, neuromodulation and endoscopy continue to compound.
  • At roughly 14 times guided 2026 adjusted EPS with a 5% free Cash Flow Yield and 28.4% adjusted operating margins, the valuation embeds a permanent growth reset; the $500 million restructuring program does not begin contributing until 2027.
  • Boston Scientific delivered better numbers than it had promised for the June quarter and lowered its full-year outlook in the same release.

A beat, a cut, and a $700 million reset

Boston Scientific (NYSE:BSX) delivered better numbers than it had promised for the June quarter and lowered its full-year outlook in the same release. Net sales of $5.442 billion on 29 July rose 7.5% as reported and 7.0% organically. Adjusted Earnings of $0.86 a share topped the company's own $0.82–$0.84 guide and the $0.83 analyst consensus, while GAAP Net Income reached $907 million, or $0.61 a share.

Management then took full-year organic growth down to 5–6% from 5–7%, reported growth to 5.5–6.5% from 7–8.5%, and adjusted EPS to $3.28–$3.32 from $3.34–$3.41. That is the second cut in three months. February's opening frame for 2026 called for 10.5–11.5% sales growth and $3.43–$3.49 in adjusted EPS, so roughly half the year's expected revenue acceleration has been withdrawn since spring.

The cost response landed a day before the results. A board-approved global restructuring, disclosed in a securities filing on 28 July, carries $700–$800 million of pre-tax charges and $600–$700 million of cash outlays, covering supply-chain redesign, plant consolidation, organizational realignment and Job cuts. The target is about $500 million of annual run-rate savings by the end of 2029, with more than half landing by the end of 2027.

Buyers absorbed the news

The stock closed at $46.73, up 1.59%. On results day it finished at $46.04, down 0.04% from the prior close, on 51.2 million shares, roughly double the recent daily average. Across the final three sessions of July the shares gained about 2.7% from $45.51 on 27 July.

Holding flat on a guidance cut counts as resilience, but the longer arc is punishing. BSX is down 56% over twelve months against a 52-week range of $42.20 to $109.50, and the 200-day Moving Average sits at $73.17, nearly 60% above the current quote. The market has already repriced the growth algorithm; the July session simply declined to reprice it again.

The parts that still compound

Cardiovascular, at $3.624 billion, grew 7.8% organically, and the segment's engine is no longer where investors assume. Interventional Cardiology and Vascular Therapies produced $1.333 billion, up 12.1% organically, with coronary therapies expanding at a double-digit clip. MedSurg contributed $1.818 billion, up 5.4% organically, led by Neuromodulation at $341 million and 12.2% growth and Endoscopy at $793 million and 7.0%. The laggards were Urology, up 0.8% to $684 million, and Cardiac Rhythm Management, down 1.6% to $585 million.

Asia-Pacific grew 11.2% operationally to $878 million and Latin America and Canada 16.2% to $206 million, outpacing the 6.2% posted in the $3.426 billion US Business .

Profitability held up better than the mix implied. Adjusted Operating Margin reached 28.4%, up 70 basis points year over year, and free cash flow rose to $1.290 billion from $1.129 billion. A gross margin near 69% remains the structural argument for the company. Boston Scientific also booked an $83 million refund of tariffs levied under emergency economic powers and completed a $2 billion accelerated share repurchase covering roughly 40 million shares. Against $1.45 billion of cash sits $11.03 billion of Debt .

Two franchises, two different problems

Watchman, the left atrial appendage closure device that grew almost 30% in 2025 to about $1.96 billion, managed $507 million and roughly 4% organic growth in the quarter, 3% in the US against 18% internationally. Management attributes the slowdown to accumulating clinical evidence reshaping referral patterns, with standalone procedures falling away while concomitant cases hold. Full-year Watchman growth is now guided to flat-to-low-single digits, implying mid-to-high-single-digit declines in the second half. Critically, the outlook assumes no recovery in 2027.

Electrophysiology is a competitive problem rather than a market one. Sales of $916 million grew 9.1% organically, with international up 23% and the US under pressure. Pulsed field ablation now accounts for roughly 80–85% of US ablation procedures, which removes the tailwind that carried Farapulse for two years: there is little radiofrequency volume left to convert. Growth from here requires holding share against Medtronic's Affera and Sphere-9 platform, Johnson & Johnson's Varipulse and Abbott's expanding portfolio. Chief executive Mike Mahoney was blunt on the call, saying the company "did undercall the competitive pressures in the U.S. in terms of share taking." Electrophysiology is guided to roughly flat in the second half, with pressure expected into the first half of 2027.

The case for a bottom

The innovation pipeline has not deteriorated alongside the guidance. At Heart Rhythm 2026, the AVANT GUARD trial in 440 persistent atrial fibrillation patients showed Farapulse achieving 56% primary effectiveness at twelve months against 30% for drug therapy, published in the New England Journal of Medicine and supporting a first-line persistent AF indication that analysts size near $1 billion by 2028. In May the company committed $1.5 billion for roughly 34% of MiRus LLC plus an exclusive option, worth up to $3 billion more on milestones, over its SIEGEL transcatheter aortic valve, now in the up-to-1,025-patient STAR pivotal trial. That is a third attempt at structural heart, funded from strength.

Margins expanded despite adverse mix, restructuring savings are additive from 2027, and trailing free cash flow of $3.48 billion supports a 5% free cash flow yield. Roughly three-quarters of the portfolio is still compounding at high-single to low-double digits.

The case that this is not the trough

Three downgrades to the same fiscal year in six months is a credibility problem, and the franchises that broke are, as Canaccord Genuity noted, among the highest-margin and fastest-growing the company owns. The third-quarter guide of 3–5% growth and $0.80–$0.82 adjusted EPS marks a further step down. Restructuring consumes $600–$700 million of cash before it yields anything, MiRus could Demand $3 billion more, and net debt already stands at $9.58 billion. Price targets fell across the board after results, Raymond James to $57 from $78, Mizuho and BTIG to $60, Canaccord to $66, even as ratings stayed positive.

Priced like an industrial, not a category leader

At $46.73 the market Capitalization is $69.46 billion and Enterprise value $79.03 billion. The forward multiple is roughly 14 times the midpoint of guided 2026 adjusted EPS, with a 3.31 price-to-sales ratio, 3.76 EV/sales and 19.0 EV/EBITDA. For a business earning 28% adjusted operating margins on 69% gross margins, that is an unusually modest rating, the market is treating 5–6% organic growth as a durable ceiling rather than a cyclical floor. Whether that judgment is right depends almost entirely on Watchman and US electrophysiology, and management has given itself until 2027 before either is assumed to improve.

Upcoming Catalysts

  • Q3 2026 results, expected late October 2026. Guidance of 3–5% growth and $0.80–$0.82 adjusted EPS sets a low bar; the read on whether Watchman's second-half decline is as steep as guided matters more than the headline.
  • Initial 2027 framework, likely with Q3 or Q4 results. Management has said only that it aims to improve on the second half of 2026. A credible 2027 algorithm is the single biggest swing Factor for the multiple.
  • Farapulse first-line persistent AF label expansion, timing not disclosed. AVANT GUARD data are in hand; an expanded indication would open an addressable market analysts have sized near $1 billion by 2028.
  • MiRus SIEGEL STAR pivotal trial enrollment and data. Progress determines whether Boston Scientific exercises a TAVR option worth up to $3 billion more.
  • Restructuring milestones through 2027. More than half of the $500 million savings target is meant to land by the end of 2027, initially in SG&A.

Principal Risks

  • Watchman may not stabilize. Company guidance already assumes no improvement in 2027. If accumulating clinical evidence continues to redirect referrals away from standalone left atrial appendage closure, a Franchise near $2 billion in annual sales could shrink rather than plateau.
  • PFA share losses could deepen. With conversion from radiofrequency largely complete in the US, growth depends on head-to-head competition with Medtronic, Johnson & Johnson and Abbott in a category where management admits it misjudged the pace of share shift.
  • Guidance credibility. Two cuts in three months, from an original 10.5–11.5% sales growth frame, raise the risk that the 5–6% organic outlook is itself optimistic.
  • Balance Sheet and capital commitments. Net debt of $9.58 billion, $600–$700 million of restructuring cash outlays and a potential $3 billion MiRus exercise constrain flexibility if operating performance slips further.
  • Tariff and policy Volatility . The quarter included an $83 million tariff refund; the underlying trade regime remains unsettled and could reverse into a cost headwind for a globally manufactured device portfolio.

Conclusion

The June quarter beat on both revenue and adjusted EPS, but full-year 2026 guidance was reduced for the second straight quarter, organic growth to 5–6%, adjusted EPS to $3.28–$3.32, and the shares still closed flat on the day. Set against that: Company guidance already assumes no improvement in 2027. That tension shows up in the valuation: At roughly 14 times guided 2026 adjusted EPS with a 5% free cash flow yield and 28.4% adjusted operating margins, the valuation embeds a permanent growth reset; the $500 million restructuring program does not begin contributing until 2027. The next real test: Guidance of 3–5% growth and $0.80–$0.82 adjusted EPS sets a low bar; the read on whether Watchman's second-half decline is as steep as guided matters more than the headline.

This article is for informational purposes only and does not constitute Investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.